Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TAC01-HER2 |
| Trade Name | |
| Synonyms | TAC 01-HER2|TAC-01-HER2|TAC-engineered T Cells TAC01-HER2 |
| Drug Descriptions |
TAC01-HER2 are autologous T-lymphocytes engineered to express an ERBB2 (HER2) T-Cell Antigen-Coupler (TAC), which leads to activation and targeting of T-lymphocytes to ERBB2 (HER2)-positive tumor cells, potentially resulting in inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr CT247). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C178298 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cyclophosphamide + Fludarabine + TAC01-HER2 | Cyclophosphamide Fludarabine TAC01-HER2 | 0 | 1 |
| TAC01-HER2 | TAC01-HER2 | 0 | 0 |